Patient Identification | PLUVICTO HCP

Identifying patients for PLUVICTO is more important than ever. AIM for PLUVICTO even earlier for your patients with PSMA+ mCRPC.^1,2

After your patients with PSMA+ mCRPC receive their first ARPI, be ready for what's next.¹ Be ready to rethink the sequence.*

*For patients considered appropriate to delay taxane-based chemotherapy.¹

Identifying Patients

AIM for Pluvicto even earlier in mCRPC¹´² AIM: After only 1 ARPI, Imaging confirms PSMA+ disease, Metastatic CRPC

1 ARPI could have been received at any point in your patient’s prostate cancer journey, including in the castration-sensitive setting^1,2

ARPI, androgen receptor pathway inhibitor; CRPC, castration-resistant prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.

Patient Profiles

MEET PATIENTS WITH PSMA+ mCRPC WHO ARE ELIGIBLE FOR PLUVICTO

Plan for PLUVICTO after only 1 ARPI, which could have been received at any point in your patient’s journey^1,2

Robert, 68: has bone/lymph metastases with asymptomatic disease. Received 1 ARPI in the mCSPC setting. Prostatectomy, Monitor (12m), ADT+ARPI (21m). Diagnosed with PSMA+ mCRPC

James, 70: has bone/lymph metastases with mildly symptomatic disease. Received 1 ARPI in the mCRPC setting. EBRT, ADT (2y), ADT+ ARPI (11m),PSMA-PET shows positive disease

Hypothetical patient cases.

ADT, androgen deprivation therapy; BCR, biochemical recurrence; EBRT, external beam radiation therapy; mCSPC, metastatic castration-sensitive prostate cancer; nmCSPC, nonmetastatic castration-sensitive prostate cancer; PET, positron emission tomography; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen.

Advancing PLUVICTO Therapy for the Right Patients

Glen Gejerman, MD, MBA, walks through what PLUVICTO therapy is, reviewing a summary of PLUVICTO data and presenting a hypothetical case of a patient with PSMA+ mCRPC, highlighting what types of patients are eligible for PLUVICTO therapy.

Care Team Perspectives for a Patient With mCSPC Who Received an ARPI and Recently Progressed to mCRPC

Nuclear medicine physician Dr Phillip J. Koo, medical oncologist Dr Scott T. Tagawa, and urologist Dr Jason M. Hafron walk through the case of a patient who previously received an ARPI for mCSPC and recently progressed to mCRPC.

Plan for PLUVICTO

GET YOUR PATIENTS ON PLUVICTO PROMPTLY AFTER ONLY 1 ARPI¹

3 ways to accelerate the PLUVICTO referral process

Order PSMA-PET scan at first sign of progression

Proactively identify PLUVICTO Treatment Centers

Find a treatment center Learn more about Novartis Patient Support

*There are over 765 PLUVICTO treatment sites in the US. Please note that the PLUVICTO Treatment Centers listed are only those that have authorized their participation on the PLUVICTO website.⁴
^†Primary plans only; an additional 1-2 days if secondary plan coverage review is required.

Planning Ahead for PLUVICTO for Patients With Advanced Prostate Cancer

Urologist Jose De La Cerda, MD, provides insights about the importance of aggressive treatment for patients with advanced prostate cancer as well as considerations about planning for PLUVICTO.

Identifying Progression in Patients With Advanced Prostate Cancer to Plan Ahead for PLUVICTO

Urologist Scott Sellinger, MD, provides insights about the importance of progression and guideline-aligned therapy options in advanced prostate cancer after an ARPI, including the importance of presenting PLUVICTO as a therapy option at first eligibility.

Optimizing Treatment in Advanced Prostate Cancer Beyond ARPI

Medical oncologist Bradley Somer, MD, shares insights on optimizing treatment in advanced prostate cancer beyond ARPI therapy, highlighting the need for continued education on logistics and key stakeholders to build HCP comfort with PLUVICTO.

Which of your patients with PSMA+ mCRPC could benefit from PLUVICTO now?

See mCRPC trial data

< Previous: mCRPC Overview

Next: Efficacy After Only 1 ARPI >

After your patients with PSMA+ mCRPC receive their first ARPI, be ready for what's next.¹ Be ready to rethink the sequence.*

MEET PATIENTS WITH PSMA+ mCRPC WHO ARE ELIGIBLE FOR PLUVICTO

Plan for PLUVICTO after only 1 ARPI, which could have been received at any point in your patient’s journey^1,2

Advancing PLUVICTO Therapy for the Right Patients

Care Team Perspectives for a Patient With mCSPC Who Received an ARPI and Recently Progressed to mCRPC

GET YOUR PATIENTS ON PLUVICTO PROMPTLY AFTER ONLY 1 ARPI¹

3 ways to accelerate the PLUVICTO referral process

Planning Ahead for PLUVICTO for Patients With Advanced Prostate Cancer

Identifying Progression in Patients With Advanced Prostate Cancer to Plan Ahead for PLUVICTO

Optimizing Treatment in Advanced Prostate Cancer Beyond ARPI

Which of your patients with PSMA+ mCRPC could benefit from PLUVICTO now?

Important Safety Information

Indication

After your patients with PSMA+ mCRPC receive their first ARPI, be ready for what's next.1 Be ready to rethink the sequence.*

MEET PATIENTS WITH PSMA+ mCRPC WHO ARE ELIGIBLE FOR PLUVICTO

Plan for PLUVICTO after only 1 ARPI, which could have been received at any point in your patient’s journey1,2

Advancing PLUVICTO Therapy for the Right Patients

Care Team Perspectives for a Patient With mCSPC Who Received an ARPI and Recently Progressed to mCRPC

GET YOUR PATIENTS ON PLUVICTO PROMPTLY AFTER ONLY 1 ARPI1

3 ways to accelerate the PLUVICTO referral process

Planning Ahead for PLUVICTO for Patients With Advanced Prostate Cancer

Identifying Progression in Patients With Advanced Prostate Cancer to Plan Ahead for PLUVICTO

Optimizing Treatment in Advanced Prostate Cancer Beyond ARPI

Which of your patients with PSMA+ mCRPC could benefit from PLUVICTO now?

After your patients with PSMA+ mCRPC receive their first ARPI, be ready for what's next.¹ Be ready to rethink the sequence.*

Plan for PLUVICTO after only 1 ARPI, which could have been received at any point in your patient’s journey^1,2

GET YOUR PATIENTS ON PLUVICTO PROMPTLY AFTER ONLY 1 ARPI¹